S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
S&P 500   4,288.05 (-0.27%)
DOW   33,507.50 (-0.47%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:EVAX

Evaxion Biotech A/S (EVAX) Stock Forecast, Price & News

$0.83
-0.02 (-2.00%)
(As of 05:11 PM ET)
Compare
Today's Range
$0.81
▼
$0.90
50-Day Range
$0.48
▼
$1.27
52-Week Range
$0.47
▼
$3.10
Volume
111,391 shs
Average Volume
316,336 shs
Market Capitalization
$23.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Evaxion Biotech A/S MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
971.4% Upside
$9.00 Price Target
Short Interest
Healthy
0.88% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.46mentions of Evaxion Biotech A/S in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

594th out of 972 stocks

Biological Products, Except Diagnostic Industry

85th out of 158 stocks

See Top Rated MarketRank™ Stocks Here

EVAX stock logo

About Evaxion Biotech A/S (NASDAQ:EVAX) Stock

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Hørsholm, Denmark.

EVAX Price History

EVAX Stock News Headlines

September 26, 2023 | americanbankingnews.com
Evaxion Biotech A/S (NASDAQ:EVAX) Stock Price Down 3.7%
September 21, 2023 | finance.yahoo.com
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
September 29, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 20, 2023 | finanznachrichten.de
Evaxion Biotech: Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
September 20, 2023 | finance.yahoo.com
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
September 18, 2023 | finance.yahoo.com
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
August 30, 2023 | bloomberg.com
Novo Buys Embark Biotech to Find New Avenues for Weight Loss
August 29, 2023 | finanznachrichten.de
Evaxion Biotech: Evaxion announces Executive Management Changes to strengthen the AI-strategy
September 29, 2023 | Behind the Markets (Ad)
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
August 29, 2023 | finance.yahoo.com
Evaxion announces Executive Management Changes to strengthen the AI-strategy
August 24, 2023 | msn.com
European Equities Traded in the US as American Depositary Receipts Rising, Backed by Mostly Firmer Markets
August 23, 2023 | finance.yahoo.com
Evaxion Biotech A/S (NASDAQ:EVAX) Q2 2023 Earnings Call Transcript
August 23, 2023 | finance.yahoo.com
Q2 2023 Evaxion Biotech A/S Earnings Call
August 18, 2023 | finanznachrichten.de
Evaxion Biotech: Evaxion Announces Business Update and Second Quarter 2023 Financial Results
August 18, 2023 | finance.yahoo.com
Evaxion Announces Business Update and Second Quarter 2023 Financial Results
August 3, 2023 | msn.com
Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst
August 1, 2023 | msn.com
Evaxion gets $20M financing from Negma
August 1, 2023 | finance.yahoo.com
Evaxion announces financing commitments totaling up to USD 20 million with Negma Group
July 31, 2023 | finance.yahoo.com
Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus
July 10, 2023 | seekingalpha.com
Iovance Biotherapeutics: More Than A One-Shot Wonder
July 8, 2023 | axios.com
Thermo Fisher to buy Audax’s CorEvitas for $913M
June 8, 2023 | foxnews.com
Cancer drug firms soar as positive clinical trial data ignites investor excitement
June 5, 2023 | marketwatch.com
ADRs End Mostly Lower, BiondVax, Evaxion Biotech Trade Actively
June 5, 2023 | news.yahoo.com
Cancer drugmakers rise as industry meet fuels investor interest
June 5, 2023 | marketwatch.com
Evaxion Biotech Shares Rise 38% After Positive EVX-01 Phase 1 Trial Data
June 5, 2023 | finance.yahoo.com
Why Are Evaxion Biotech Shares Trading Higher Today
June 3, 2023 | finance.yahoo.com
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
See More Headlines
Receive EVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter.

EVAX Company Calendar

Last Earnings
8/22/2023
Today
9/29/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EVAX
CUSIP
N/A
CIK
1828253
Web
www.evaxion-biotech.com
Phone
45-5353-1850
Fax
N/A
Employees
63
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+958.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-23,170,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-452.78%
Return on Assets
-126.54%

Debt

Debt-to-Equity Ratio
3.95
Current Ratio
2.81
Quick Ratio
2.81

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
2.43

Miscellaneous

Outstanding Shares
27,650,000
Free Float
16,138,000
Market Cap
$23.50 million
Optionable
Not Optionable
Beta
0.53
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Niels Iversen Moeller M.D. (Age 44)
    Co-Founder, VP of Bus. & Director
    Comp: $120k
  • Mr. Andreas Holm Mattsson (Age 47)
    Co-Founder and Chief AI & Culture Officer
    Comp: $319k
  • Mr. Jesper Nyegaard Nissen (Age 53)
    CFO & COO
    Comp: $346.97k
  • Dr. Birgitte Rono Ph.D. (Age 47)
    Chief Scientific Officer
    Comp: $336k
  • Mr. Christian Kanstrup (Age 51)
    Chief Exec. Officer
  • Dr. Jürgen Langhärig EMBA
    Ph.D., Head of Bus. Devel. & Member of Advisory Board

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













EVAX Stock - Frequently Asked Questions

Should I buy or sell Evaxion Biotech A/S stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evaxion Biotech A/S in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EVAX shares.
View EVAX analyst ratings or view top-rated stocks.

What is Evaxion Biotech A/S's stock price forecast for 2023?

2 Wall Street analysts have issued 12-month target prices for Evaxion Biotech A/S's stock. Their EVAX share price forecasts range from $7.00 to $11.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 958.8% from the stock's current price.
View analysts price targets for EVAX or view top-rated stocks among Wall Street analysts.

How have EVAX shares performed in 2023?

Evaxion Biotech A/S's stock was trading at $1.7750 at the beginning of 2023. Since then, EVAX shares have decreased by 52.1% and is now trading at $0.85.
View the best growth stocks for 2023 here.

Are investors shorting Evaxion Biotech A/S?

Evaxion Biotech A/S saw a increase in short interest in September. As of September 15th, there was short interest totaling 242,800 shares, an increase of 38.5% from the August 31st total of 175,300 shares. Based on an average daily volume of 112,500 shares, the days-to-cover ratio is currently 2.2 days.
View Evaxion Biotech A/S's Short Interest.

When is Evaxion Biotech A/S's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our EVAX earnings forecast.

How were Evaxion Biotech A/S's earnings last quarter?

Evaxion Biotech A/S (NASDAQ:EVAX) issued its quarterly earnings data on Tuesday, August, 22nd. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01.

When did Evaxion Biotech A/S IPO?

(EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at a price of $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

What is Evaxion Biotech A/S's stock symbol?

Evaxion Biotech A/S trades on the NASDAQ under the ticker symbol "EVAX."

How do I buy shares of Evaxion Biotech A/S?

Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evaxion Biotech A/S's stock price today?

One share of EVAX stock can currently be purchased for approximately $0.85.

How much money does Evaxion Biotech A/S make?

Evaxion Biotech A/S (NASDAQ:EVAX) has a market capitalization of $23.50 million. The company earns $-23,170,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How can I contact Evaxion Biotech A/S?

Evaxion Biotech A/S's mailing address is BREDGADE 34E, COPENHAGEN K G7, 1260. The official website for the company is www.evaxion-biotech.com. The company can be reached via phone at 45-5353-1850 or via email at info@evaxion-biotech.com.

This page (NASDAQ:EVAX) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -